Evidence map›Paper›PMID 21963833›Full record

ArticleAmerican journal of physiology. Heart and circulatory physiology2011

Intramuscular VEGF activates an SDF1-dependent progenitor cell cascade and an SDF1-independent muscle paracrine cascade for cardiac repair.

David Zisa, Arsalan Shabbir, Michalis Mastri, Tyler Taylor, Ilija Aleksic, Mary McDaniel, Gen Suzuki, Techung Lee

Abstract read
In one paragraph

Article in American journal of physiology. Heart and circulatory physiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Cardiac regeneration and diabetes.Regenerative medicine research · 2014
    Review
  13. Review
  14. Article
  15. Article
  16. Stem cell therapy independent of stemness.World journal of stem cells · 2012
    Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

David ZisaDepartment of Biochemistry and Biomedical Engineering, Center for Research in Cardiovascular Medicine, University at Buffalo, New York, USA.
Arsalan Shabbir
Michalis Mastri
Tyler Taylor
Ilija Aleksic
Mary McDaniel
Gen Suzuki
Techung Lee
University at Buffalo, State University of New York · US

Funding

Mesenchymal Stem Cell Therapeutics in Hibernating MyocardiumR01HL084590 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI LEE, TECHUNG · 2006 to 2010
$1.9M
NHLBI NIH HHS R01-HL-84590
6 · The paper itself

Abstract

The skeletal muscle is endowed with an impressive ability to regenerate after injury, and this ability is coupled to paracrine production of many trophic factors possessing cardiovascular benefits. Taking advantage of this humoral capacity of the muscle, we recently demonstrated an extracardiac therapeutic regimen based on intramuscular delivery of VEGF-A(165) for repair of the failing hamster heart. This distal organ repair mechanism activates production from the injected hamstring of many trophic factors, among which stromal-derived factor-1 (SDF1) prominently mobilized multi-lineage progenitor cells expressing CXCR4 and their recruitment to the heart. The mobilized bone marrow progenitor cells express the cardiac transcription factors myocyte enhancer factor 2c and GATA4 and several major trophic factors, most notably IGF1 and VEGF. SDF1 blockade abrogated myocardial recruitment of CXCR4(+) and c-kit(+) progenitor cells with an insignificant effect on the hematopoietic progenitor lineage. The knockdown of cardiac progenitor cells led to deprivation of myocardial trophic factors, resulting in compromised cardiomyogenesis and angiogenesis. However, the VEGF-injected hamstring continued to synthesize cardioprotective factors, contributing to moderate myocardial tissue viability and function even in the presence of SDF1 blockade. These findings thus uncover two distinct but synergistic cardiac therapeutic mechanisms activated by intramuscular VEGF. Whereas the SDF1/CXCR4 axis activates the progenitor cell cascade and its trophic support of cardiomyogenesis intramuscularly, VEGF amplifies the skeletal muscle paracrine cascade capable of directly promoting myocardial survival independent of SDF1. Given that recent clinical trials of cardiac repair based on the use of marrow-mobilizing agents have been disappointing, the proposed dual therapeutic modality warrants further investigation.

Indexed as

AnimalsAntibodiesApoptosisCardiomyopathiesCells, CulturedChemokine CXCL12ChemotaxisCricetinaeDisease Models, AnimalInjections, IntramuscularMesenchymal Stem CellsMuscle, SkeletalMyocardiumNeovascularization, PhysiologicParacrine CommunicationProto-Oncogene Proteins c-kitAntibodiesChemokine CXCL12Proto-Oncogene Proteins c-kitReceptors, CXCR4Recombinant ProteinsTranscription FactorsVascular Endothelial Growth Factor A

Identifiers

PMID21963833
PMCPMC3233810
OpenAlexW1984007061

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.